Abstract
To address the immune mechanism sustaining interferon beta (IFNbeta) efficacy in multiple sclerosis (MS), we longitudinally analyzed expressions of IFN-gamma, IL-4, IL-5 and IL-13 in CD4+ T cells and CD8+ T cells in 22 Japanese MS patients (16 patients with conventional MS and 6 with opticospinal MS) undergoing IFNbeta using flow cytometry. During the 48-week observation period, five opticospinal MS patients (83%) relapsed compared to only four conventional MS patients (25%); the frequency of relapsed patients was significantly higher in the former (p=0.046). The effects of IFNbeta on individual cytokines were time-dependent and altered cytokine productions were particularly evident in CD4+ rather than CD8+ T cells. A decreased intracellular IFN-gamma/IL-4 ratio in CD4+ T cells was thus evident soon after the initiation of therapy, and persisted for the entire 1 year follow-up period, regardless of whether or not the patient relapsed (p<0.01). IFNbeta treatment resulted in a rapid increase in the percentage of IFN-gamma- IL-4+ and IL-13+ CD4+ T cells 1 week after the initiation of therapy and high values were sustained for 6 months but declined to the baseline over 1 year. Later, the percentage of IFN-gamma+ IL-4- CD4+ T cells ...Continue Reading
References
Nov 1, 1983·Neurology·J F Kurtzke
Jan 1, 1994·Annual Review of Neuroscience·L SteinmanJ R Oksenberg
Dec 1, 1995·Neurology·A S DayalB G Arnason
Oct 1, 1996·Annals of Neurology·J KiraT Kobayashi
Dec 20, 1996·Science·C P GenainS L Hauser
Jul 21, 1997·The Journal of Experimental Medicine·J J LafailleS Tonegawa
Dec 31, 1997·The Journal of Experimental Medicine·B ZhangT Tabira
Jun 6, 1998·The Journal of Experimental Medicine·C Bogdan
Sep 25, 1998·Neurology·V W YongG Williams
Sep 1, 1999·Brain : a Journal of Neurology·K YamasakiJ Kira
Sep 28, 1999·Current Opinion in Neurology·G Martino, H P Hartung
Jan 6, 2000·Journal of the Neurological Sciences·I HoriuchiJ i Kira
Feb 17, 2000·Cellular Immunology·R C van der VeenW Gilmore
Sep 1, 2000·Journal of the Neurological Sciences·X M WuJ I Kira
May 24, 2001·Current Opinion in Neurology·C L KarpL Nagelkerken
Jul 18, 2001·Annals of Neurology·W I McDonaldJ S Wolinsky
Sep 18, 2001·Annals of Neurology·K P WandingerR Martin
Oct 5, 2001·Journal of Neuroimmunology·H OchiJ Kira
Mar 23, 2002·Autoimmunity·Alan G Baxter, Mark J Smyth
Aug 7, 2002·Journal of the Neurological Sciences·Hirofumi OchiJun-ichi Kira
Apr 2, 2003·Journal of Neuroimmunology·Paul GniadekFrauke Zipp
Dec 4, 2003·Journal of Neuroimmunology·Lorne F KastrukoffDonald W Paty
Citations
Sep 20, 2012·BMC Neurology·Celia Oreja-GuevaraExuperio Diez-Tejedor
Nov 26, 2009·Rinshō shinkeigaku = Clinical neurology·Jun-ichi Kira
Feb 13, 2015·Rinshō shinkeigaku = Clinical neurology·Jun-ichi Kira
Jun 6, 2008·Neurochemistry International·Johann SellnerHeinrich P Mattle
Feb 24, 2015·Cytokine·Dusanka S SkundricHarley Y Tse
May 15, 2009·Headache·Hikaru DoiJun-ichi Kira
Apr 4, 2006·Journal of the Neurological Sciences·Feng-Jun MeiJun-ichi Kira
Jul 16, 2014·The International Journal of Neuroscience·Belgin Petek-BalcıMefküre Eraksoy
Jun 2, 2012·Cytokine·Murat KürtüncüMefküre Eraksoy
Apr 29, 2015·PloS One·Zi-Ye SongJun-ichi Kira
May 26, 2009·Multiple Sclerosis : Clinical and Laboratory Research·T MatsushitaJ I Kira
May 4, 2007·Endocrine Reviews·Mario RotondiPaola Romagnani
Jul 20, 2019·The British Journal of Dermatology·E PetersonA G Franks
Jun 20, 2018·Frontiers in Immunology·Chiara D'AngeloLivia Pasquali
Apr 23, 2021·International Journal of Clinical Practice·Hazal GezmisDeniz Kirac